News – Page 729 – Endpoints News

An Array co-founder re-emerges as CEO of a small academic spinout, looking to remake an old class of cancer drugs

5 years ago

Brii Bio joins the NIH graveyard alongside GSK, Lilly after flopping antibody study in hospitalized Covid-19 patients

5 years ago

Focusing on the bright side, FDA OKs Roche's Actemra for rare lung disease despite PhIII flop

5 years ago

After three years of courtship (and turndowns), Merck pounced on the first glance of clinical data in $1.85B Pandion ...

5 years ago

Apellis joins the growing number of biopharmas scrapping a failed Covid-19 program after an early flop

5 years ago

Kronos seals pact with regulators to hunt AML with previously off-limits biomarker endpoint

5 years ago

Pfizer's Xalkori follow-up, which smoked the older drug in 1st-line patients, scores double win at the FDA

5 years ago

Galapagos posts a safety win for filgotinib, but is it too little, too late?; Bio-Techne inks $320M molecular ...

5 years ago

Novartis pairs up with CureVac to help drive Covid-19 shot production but may miss the show in the US, EU

5 years ago

Amgen snaps up cancer drug player Five Prime, adding PhIII-ready FGFR2b drug in $2B M&A play

5 years ago

In the latest big investment in gene therapy manufacturing, Biogen commits $200M to a major new facility in NC

5 years ago

With $117M in fresh cash, Amunix paves path to the clinic for 'universal mask' prodrug on the hunt for HER2 tumors

5 years ago

Covid-19 roundup: EMA starts rolling review of Russia's Sputnik V; Novavax says shot is 51% effective against variant ...

5 years ago

BlackRock pushes Exscientia Series C to $100M as AI biotech boom continues

5 years ago

Latest MassBio report shows just how much biopharma's biggest sector boomed in 2020

5 years ago

David Liu has a new big idea: proteome editing. It could one day shred tau, RAS and some of the worst disease-causing ...

5 years ago

Eli Lilly claims a TKO in its long-running title fight with Novo Nordisk for the blockbuster diabetes market — but ...

5 years ago

Amid back office consolidation, Gilead axes 179 jobs in California

5 years ago

Peter Thiel-backed psychedelics player ATAI pulls in another nine-figure raise. But they're not ready to talk IPO — ...

5 years ago

Sofinnova Partners stays focused on late-stage deals with a new, $540M crossover fund

5 years ago

GSK, Vir's hopes for a Covid-19 antibody fall flat in NIH 'master protocol' with no benefit in hospitalized patients

5 years ago

Presage teams with Merck on its Phase 0 testing; KemPharm ADHD drug wins approval in children aged 6 and up

5 years ago

As BrainStorm continues to tout ‘clear signal’ on ALS drug, the FDA offers a rare public slapdown on the data

5 years ago

United axes PAH program Trevyent, once bought for cheap in acquisition of a rival, after FDA feedback

5 years ago

First page Previous page 726 727 728729730 731 732 Next page Last page